LYNPARZA: payments to doctors
Payments that named LYNPARZA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $22.5M
- Providers
- 25,876
- Transactions
- 142,834
- Average per transaction
- $157
The per-transaction average — $157 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 25,876 providers the average total is $869, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| AstraZeneca | $18,445,603 | 82.1% |
| Merck | $3,260,668 | 14.5% |
| Astrazeneca UK Limited | $758,605 | 3.4% |
| Acerta Pharma LLC | $11,012 | 0.0% |